Biogen (HAM:IDP) Treasury Stock: €-2,575 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:IDP Biogen Inc HAM:IDP
74 GF Score
Price €182.58
GF Value €170.36
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Treasury Stock?

Biogen HAM:IDP +2.26% 74 Treasury Stock is €-2,575 Mil as of Mar. 2026. GuruFocus rates HAM:IDP with a GF Score™ of 74/100 and a GF Value™ of €170.36 (Fairly Valued). The stock has 7 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Biogen's treasury stock for the quarter that ended in Mar. 2026 was €-2,575 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Biogen Treasury Stock Historical Data

* Premium members only.

The historical data trend for Biogen's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Treasury Stock Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,634.73 -2,810.38 -2,730.00 -2,843.13 -2,542.44

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,753.82 -2,581.15 -2,536.49 -2,542.44 -2,575.19
HAM:IDP
74GF Score
Biogen Inc HAM:IDP
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €-2,575 Mil mean?
Biogen (HAM:IDP) has a Treasury Stock of €-2,575 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Biogen and its competitors.
Is Biogen's Treasury Stock too high?
Biogen's current Treasury Stock is €-2,575 Mil. Overall, Biogen has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Treasury Stock compare to OGN and AMRN?
Biogen's Treasury Stock of €-2,575 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Drug Manufacturers company?
A good Treasury Stock depends on the Drug Manufacturers industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Biogen and its competitors. Biogen's current Treasury Stock is €-2,575 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €170.36, compared to a current price of €182.58 — trading 7.2% above its estimated fair value. The current Treasury Stock is €-2,575 Mil. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Treasury Stock is €-2,575 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €182.58 is trading 7.2% above its estimated GF Value™ of €170.36. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for HAM:IDP:

  • Treasury Stock: €-2,575 Mil
  • GF Value™: €170.36 vs. price of €182.58 (7.2% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for HAM:IDP

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€182.58
Price
€170.36
GF Value